Cover Image
市場調查報告書

雄性脫毛症 - 開發中產品分析

Androgenic Alopecia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 257832
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
雄性脫毛症 - 開發中產品分析 Androgenic Alopecia - Pipeline Review, H2 2016
出版日期: 2016年12月30日 內容資訊: 英文 70 Pages
簡介

雄激素(男性荷爾蒙)性脫髮症是遺傳性疾病,其特微為由硬髮階段性轉變為柔軟毛髮。男女皆常見,是非常普遍的疾病。致病因子有過敏、刺激物、毒素、燙傷、外傷、感染疾病等。

本報告提供雄性脫毛症治療藥的開發情形調查分析,提供您開發中產品的概要,臨床實驗各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

雄性脫毛症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

治療藥的開發企業

  • Allergan, Inc.
  • Histogen, Inc.
  • R-Tech Ueno, Ltd.
  • Hygeia Therapeutics, Inc.
  • SWITCH Biotech LLC
  • Polichem S.A.
  • Kasiak Research Pvt. Ltd.

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • bimatoprost
  • RK-023
  • Refagro
  • RCH-01
  • Hair Stimulating Complex (HSC)
  • finasteride
  • SM-04554
  • HYG-440
  • (HYG-102 + HYG-440)
  • Small Molecule for Androgenic Alopecia

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8897IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Androgenic Alopecia - Pipeline Review, H2 2016, provides an overview of the Androgenic Alopecia (Dermatology) pipeline landscape.

Androgeneic alopecia is a genetically determined disorder characterized by the gradual conversion of terminal hairs into indeterminate, and finally into vellus, hairs. It is an extremely common disease that affects men and women. Predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Androgenic Alopecia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Androgenic Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Androgenic Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Androgenic Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 8, 4 and 1 respectively.

Androgenic Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Androgenic Alopecia (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Androgenic Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Androgenic Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Androgenic Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Androgenic Alopecia (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Androgenic Alopecia (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Androgenic Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Androgenic Alopecia Overview
  • Therapeutics Development
    • Pipeline Products for Androgenic Alopecia - Overview
  • Androgenic Alopecia - Therapeutics under Development by Companies
  • Androgenic Alopecia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Androgenic Alopecia - Products under Development by Companies
  • Androgenic Alopecia - Companies Involved in Therapeutics Development
    • Aclaris Therapeutics Inc
    • Allergan Plc
    • Almirall SA
    • BiologicsMD Inc
    • Dong-A Socio Holdings Co Ltd
    • Histogen Inc
    • RepliCel Life Sciences Inc
    • RiverTown Therapeutics Inc
    • Samumed LLC
    • Sucampo Pharmaceuticals Inc
    • SWITCH Biotech LLC
  • Androgenic Alopecia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (cyclosporine A + minoxidil + RT-175) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bimatoprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMD-1341 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BRM-421 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-0301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • finasteride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • finasteride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HGEN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RCH-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RK-023 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • setipiprant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-04554 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Androgenic Alopecia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK for Alopecia Areata, Androgenetic Alopecia and Dermatological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Androgenic Alopecia - Dormant Projects
  • Androgenic Alopecia - Discontinued Products
  • Androgenic Alopecia - Product Development Milestones
    • Featured News & Press Releases
      • Oct 25, 2016: Samumed Successfully Completes a Phase II Androgenetic Alopecia Biopsy Trial Studying Regeneration of Hair Follicles
      • Sep 26, 2016: RepliCel Provides Update on Shiseido License and Co-Development for RCH-01
      • Jul 21, 2016: RepliCel Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan
      • Mar 07, 2016: Samumed Presents At The Annual Meeting Of The American Academy Of Dermatology Safety And Efficacy Results From Its Phase 2 Androgenetic Alopecia Trial
      • Feb 24, 2016: Cassiopea attains clinical endpoints in Breezula alopecia proof of concept trial
      • Dec 04, 2015: Samumed Announces Increases in Both Hair Count and Hair Density Observed in Its Phase II Study for a Potential Treatment of Androgenetic Alopecia
      • Nov 23, 2015: Samumed Completes Phase II Study for Its Potential Treatment of Androgenetic Alopecia: Safety Data Show No Serious Adverse Events in Any Treated Patient
      • Nov 18, 2015: Samumed to Announce Clinical Data on Potential Treatment of Androgenetic Alopecia at the World Congress for Hair Research
      • Dec 22, 2014: Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness
      • Oct 09, 2014: RepliCel to Present Commercial and Clinical Update at BioJapan 2014 World Business Forum
      • May 20, 2014: RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness
      • Feb 27, 2014: RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine
      • Jan 13, 2014: RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology
      • Dec 19, 2013: RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Androgenic Alopecia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Androgenic Alopecia - Pipeline by Aclaris Therapeutics Inc, H2 2016
  • Androgenic Alopecia - Pipeline by Allergan Plc, H2 2016
  • Androgenic Alopecia - Pipeline by Almirall SA, H2 2016
  • Androgenic Alopecia - Pipeline by BiologicsMD Inc, H2 2016
  • Androgenic Alopecia - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016
  • Androgenic Alopecia - Pipeline by Histogen Inc, H2 2016
  • Androgenic Alopecia - Pipeline by RepliCel Life Sciences Inc, H2 2016
  • Androgenic Alopecia - Pipeline by RiverTown Therapeutics Inc, H2 2016
  • Androgenic Alopecia - Pipeline by Samumed LLC, H2 2016
  • Androgenic Alopecia - Pipeline by Sucampo Pharmaceuticals Inc, H2 2016
  • Androgenic Alopecia - Pipeline by SWITCH Biotech LLC, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Androgenic Alopecia - Dormant Projects, H2 2016
  • Androgenic Alopecia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Androgenic Alopecia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top